| Page 204 | Kisaco Research
  • How employers are integrating fertility, menopause, and maternal health into employee health plans.
  • Addressing workplace challenges like menstrual health, caregiving, and chronic conditions.
  • The ROI of Women's Health Investment – How employer-driven health initiatives improve retention.
Brain Health
Nutrition and Food as Medicine
Healthcare Costs and Outcomes

Author:

Maxine Carrington

Chief People Officer
Northwell Health

Maxine Carrington

Chief People Officer
Northwell Health

Author:

Jennesa Atherton

Head of Clinical Affairs
Sword Health

Jennesa Atherton

Head of Clinical Affairs
Sword Health
  • Exploring how housing, nutrition, identity, and income shape maternal outcomes.
  • Highlighting programs and solutions that integrate social support with clinical care.
  • Discussing actionable strategies in the clinical setting that embed accessibility and education into maternal health systems.
Nutrition and Food as Medicine
Maternal Health

Author:

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Mass General Brigham

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Mass General Brigham

Author:

Eva Luo

OBGYN & Head of Obstetrics, Design & Delivery
Pomelo Care

Eva Luo

OBGYN & Head of Obstetrics, Design & Delivery
Pomelo Care

Author:

Pooja Mehta

Vice President, Population Health
Cityblock Health

Pooja Mehta

Vice President, Population Health
Cityblock Health

Author:

Lucy Perez

Senior Partner, McKinsey & Co
Global Leader, McKinsey Health Institute

Lucy is a Senior Partner in McKinsey’s Boston office. Lucy has 15+ years of experience advising CEOs and top teams at leading pharma, biotech and life sciences companies globally on growth strategy, innovation, sustainability, and organizational transformation.

Lucy co-leads McKinsey’s ESG domain and McKinsey’s All-In DEI efforts in North America.  She also sponsors the Hispanic Latino Network at McKinsey and leads our research efforts on health equity.

Lucy works extensively with number of biopharma and life science clients on broad range of topics, with recent focus on ESG/ sustainability, evidence generation, and digital/analytics programs to improve patient outcomes and support sustainable, inclusive growth.

Led efforts for a leading biopharma to define their ESG strategy, partnership strategy, and stakeholder engagement approach

Led efforts for a leading biopharma to embed health equity as a core principle in their R&D priorities and ways of working across the value chain

Led efforts to assess internal and external portfolio productivity and pricing models to optimize the R&D strategy and redesign the organization for a top pharmaceutical company

Led efforts for a leading biopharma to transform how it engages with customers through digital transformation, applying advanced analytics and embedding agile ways of working across their six largest markets that delivered $300M+ of near-term growth

Sponsor of McKinsey’s Early Stage Investor Conference, an annual event convening 200+ entrepreneurs and 1000+ investors interested in bio/med/health tech and sustainability innovation

Before joining McKinsey, Lucy was a research fellow at Memorial Sloan-Kettering Cancer Center, where she was involved in the development of novel treatments for solid tumors. She was also a Howard Hughes Medical Institute research fellow at Harvard University while completing her doctoral studies. She is co-inventor on multiple patents and has published in peer-reviewed journals.

Lucy Perez

Senior Partner, McKinsey & Co
Global Leader, McKinsey Health Institute

Lucy is a Senior Partner in McKinsey’s Boston office. Lucy has 15+ years of experience advising CEOs and top teams at leading pharma, biotech and life sciences companies globally on growth strategy, innovation, sustainability, and organizational transformation.

Lucy co-leads McKinsey’s ESG domain and McKinsey’s All-In DEI efforts in North America.  She also sponsors the Hispanic Latino Network at McKinsey and leads our research efforts on health equity.

Lucy works extensively with number of biopharma and life science clients on broad range of topics, with recent focus on ESG/ sustainability, evidence generation, and digital/analytics programs to improve patient outcomes and support sustainable, inclusive growth.

Led efforts for a leading biopharma to define their ESG strategy, partnership strategy, and stakeholder engagement approach

Led efforts for a leading biopharma to embed health equity as a core principle in their R&D priorities and ways of working across the value chain

Led efforts to assess internal and external portfolio productivity and pricing models to optimize the R&D strategy and redesign the organization for a top pharmaceutical company

Led efforts for a leading biopharma to transform how it engages with customers through digital transformation, applying advanced analytics and embedding agile ways of working across their six largest markets that delivered $300M+ of near-term growth

Sponsor of McKinsey’s Early Stage Investor Conference, an annual event convening 200+ entrepreneurs and 1000+ investors interested in bio/med/health tech and sustainability innovation

Before joining McKinsey, Lucy was a research fellow at Memorial Sloan-Kettering Cancer Center, where she was involved in the development of novel treatments for solid tumors. She was also a Howard Hughes Medical Institute research fellow at Harvard University while completing her doctoral studies. She is co-inventor on multiple patents and has published in peer-reviewed journals.

 

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Mass General Brigham

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Mass General Brigham

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Mass General Brigham
  • Concrete guidance on accessing non-dilutive and dilutive funding - what’s available, what’s working, and how to get it.
  • Strategies for founders and funders to navigate uncertainty and build investable, scalable ventures in women's health.
  • How women, as both innovators and investors, are transforming the funding ecosystem - and how to leverage that shift now.
Digital Health
Innovation and Investment

Author:

Lisa Marceau

CEO
Joyuus

Lisa Marceau

CEO
Joyuus
  • Sharing new clinical outcomes and how clinical trials are evolving.
  • Exploring the link between menopause, estrogen, and cognitive decline.
  • How biomarkers, digital tools, and lifestyle interventions can improve outcomes.
Brain Health

Author:

Anna Valcheva

Founder and CEO Astra Ventures; Venture Partner and Advisor
Alumni Ventures Group

Anna Valcheva

Founder and CEO Astra Ventures; Venture Partner and Advisor
Alumni Ventures Group

Author:

James Hamet

CEO
Vistim Labs

James Hamet

CEO
Vistim Labs

Author:

Kristine Burke

CEO
True Health Center for Precision Medicine

Kristine Burke

CEO
True Health Center for Precision Medicine
  • Sharing the role of technology and partnerships in the design & recruitment of studies.
  • Highlighting adaptive trial designs, decentralized models, and inclusive recruitment strategies.
  • Exploring how smarter trial design accelerates approval, reduces risk, and improves real-world outcomes.
Reproductive Health
Drug Development
Med Device
  • Demystifying product-market fit in the context of digital health, where clinical need, usability, and reimbursement must align.
  • Identifying key indicators—user adoption, engagement, and outcomes—that show readiness to scale.
  • Strategies for translating validated need into scalable, sustainable digital health solutions.
Innovation and Investment
  • Discuss strategies for trial design that account for hormonal fluctuations, comorbidities, and age-related variables unique to the menopausal transition.
  • Highlight regulatory, industry, and advocacy efforts that are pushing for menopause-specific representation in therapeutic areas beyond just women’s health.
  • Sharing advancements to educate clinical trial patients about menopause.
Menopause and Longevity
Drug Development
 

Johan van Hylckama

CSO
Freya Biosciences

Johan van Hylckama

CSO
Freya Biosciences

Johan van Hylckama

CSO
Freya Biosciences